Blood samples from lung cancer patients taking tyrosine kinase inhibitors
Repeated blood samples are collected from adults with lung cancer starting tyrosine kinase inhibitors.
Plain-language title generated from the registry record
Registry title: ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
Key facts
- Where
- Rotterdam, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer who have a driver gene change and are treated with a tyrosine kinase inhibitor. Blood samples will be taken repeatedly.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Locally advanced or metastatic non-small cell lung cancer (NSCLC)
- Earlier treatment
- Treatment with a tyrosine kinase inhibitor (TKI) as standard of care
- Biomarker or test result
- An oncogenic driver mutation
Main reasons for not taking part
- Blood cannot be drawn for study purposes
Read by machine on 12 November 2026.
Where in Netherlands
- Erasmus MCRotterdam, NetherlandsContact: Anne-Marie Dingemans, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Erasmus Medical Center
- Trial code
- NCT05221372
- Record updated
- 18 February 2022
- Original description
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.Read full original descriptionShow less
proSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.
Inclusion: Age ≥ 18 years; Able to understand the written informed and able to give informed consent; Locally advanced or metastatic NSCLC with oncogenic driver mutation; Treatment with TKI according to standard of care.
Exclusion: Unable to draw blood for study purposes.